首页> 美国卫生研究院文献>Indian Heart Journal >Upscaling cardiac assist devices in decompensated heart failure: Choice of device and its timing
【2h】

Upscaling cardiac assist devices in decompensated heart failure: Choice of device and its timing

机译:在失代偿性心力衰竭中升级心脏辅助设备:设备的选择及其时机

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Advanced heart failure is a heterogeneous condition unified by a very high mortality unless right treatment is instituted at the right time. The first step is understanding the mechanism leading to instability: hemodynamic or ischemic. Right kind of therapy; drugs (ionotropic) or IABP or other cardiac assist devices should be chosen according to mechanism of insult as well as degree of insult. Drugs such as ionotropes are effective only in very early course but if the decompensation has progressed beyond a certain point device such as IABP may be effective but again only early in the course when CPO? 0.6. Beyond a certain point, even IABP may not be effective: here only Impella (2.5, CP or 5) or Tandem Heart may be effective. However, beyond a certain point CPO < 0.53, even these devices may not be effective. Thus crux of the matter is choice of a right device/drug and timing of its institution.
机译:除非在正确的时间进行正确的治疗,否则晚期心力衰竭是一种由很高的死亡率统一起来的异质性疾病。第一步是了解导致不稳定的机理:血液动力学或局部缺血。正确的治疗方法;药物(离子性药物)或IABP或其他心脏辅助装置应根据损伤的机理以及损伤的程度进行选择。诸如离子性药物等药物仅在非常早期的过程中有效,但如果代偿失调已经超过某个点,例如IABP可能有效,但仅在CPO早期才有效。 0.6。超出某个点,甚至IABP也可能无效:此处仅Impella(2.5,CP或5)或Tandem Heart可能有效。但是,超出CPO <0.53的某个点,即使这些设备也可能无效。因此,问题的症结在于选择正确的器械/药品及其时机。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号